Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 10512345...102030...Last »

Celgene Ends Navicixizumab Licensing Deal with OncoMed

Shares of OncoMed Pharmaceuticals fell after the company announced that Celgene walked away from a deal to license the bispecific antibody navicixizumab.

Read More »

Amicus Therapeutics Buys Celenex

Amicus Therapeutics inked a definitive agreement for 10 gene therapy programs licensed from Nationwide Children’s Hospital through the acquisition of Celenex.

Read More »

Molecular Templates, Takeda Strike MM Deal

Shares of Molecular Templates were up more than 52 percent after announcing a deal with Takeda that could be worth up to $632 million to develop CD38-targeted engineered toxin bodies.

Read More »

Animal health firm Elanco surges 36 percent in debut

Elanco Animal Health’s shares climbed 36 percent in their stock market debut, in a sign of investor enthusiasm for the fast-growing pet healthcare market.

Read More »

Celltrion Signs ‘Incubation’ Agreement with Emory University for Development of New Drugs for Atherosclerosis

Celltrion Inc. signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.

Read More »

AstraZeneca plots China robot offensive to counter price cuts

With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China.

Read More »

California insurance regulator sues AbbVie alleging Humira kickbacks

Insurance Commissioner Dave Jones filed a complaint on behalf of the State of California against AbbVie Inc., alleging the drugmaker gave illegal kickbacks to healthcare providers to prescribe the company’s blockbuster medicine Humira.

Read More »

Clovis Oncology, execs to pay $20 million to settle SEC charges

U.S. biotechnology company Clovis Oncology Inc., Chief Executive Patrick Mahaffy, and former CFO Erle Mast will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said.

Read More »

Second Scientist Pleads Guilty to Stealing GlaxoSmithKline Trade Secrets

A second former GlaxoSmithKline scientist pled guilty to stealing trade secrets as part of a scheme to benefit a startup China-based pharmaceutical company he helped establish.

Read More »

Viking shares surge after fatty liver drug trial

Viking Therapeutics Inc.’s shares more than doubled in value after promising data from a mid-stage trial of the company’s fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals.

Read More »

Novo Nordisk lays off 400 staff in R&D unit

Novo Nordisk said the world’s top maker of diabetes drugs will lay off 400 staff in Denmark and China as part of a broader restructuring of the company’s research and development organization.

Read More »

Cigna/Express Scripts deal gets antitrust nod

Health insurer Cigna Corp.’s $52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co. passed U.S. antitrust scrutiny, the companies said.

Read More »

Realm Therapeutics Slashes Staff and Explores Potential Sale as the Company Conducts a Strategic Review

Realm Therapeutics opted to discontinue all drug development programs and is considering a potential sale of the Malvern, Pa.-based company following a clinical trial failure with the atopic dermatitis treatment PR022.

Read More »

CRISPR Therapeutics and ViaCyte Collaborate to Tackle Type 1 Diabetes

CRISPR Therapeutics and ViaCyte are collaborating to discover, develop and commercialize a gene-edited allogeneic stem cell therapy or therapies for diabetes.

Read More »

Coke eying cannabis-infused drink market

Coca-Cola Co. is closely watching the growing marijuana-infused drinks market, responding to a media report that the world’s largest beverage maker was in talks with Canada’s Aurora Cannabis Inc.

Read More »

Botox Maker Allergan Buys Aesthetic Company Bonti

Dublin-based Allergan is acquiring Newport Beach, California-based Bonti with an upfront payment of $195 million.

Read More »

How better search tools can help pharma increase productivity and advance drug development

If you are a clinical researcher or scientist, you are well-aware of the inefficiencies of current search processes that require hours of time wading through data to find hidden nuggets of valuable info.

Read More »

Supernus Pharma to Buy Biscayne Neurotherapeutics in Potential $183 Million Deal

Rockville, Maryland-based Supernus Pharmaceuticals is acquiring Biscayne Neurotherapeutics, which is located in Miami.

Read More »

Sanofi pledges to keep up restructuring efforts

Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, while several of the company’s key drugs are selling well.

Read More »

Medtech Company Endotronix Snags $45 Million in Series D Funding

Lisle, Ill.-based medtech company Endotronix Inc. secured $45 million in a Series D financing round.

Read More »

Page 1 of 10512345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom